Key Highlights

  • Integra LifeSciences (NASDAQ:IART) reported on Wednesday, October 21, 2026 that it completed a USD 2.1 billion refinancing two days earlier, including USD 450 million of 9.5% senior secured notes due 2033.
  • Adjusted EPS was USD 0.59, against the consensus estimate of USD 0.56 and within the USD 0.53 to USD 0.61 guidance flagged before results, while revenue rose 2.3% to USD 411.2 million.
  • Free cash flow rose to USD 85.7 million from USD 25.8 million, net debt fell to USD 1.52 billion and the consolidated total leverage ratio stood at 3.8 times.
  • The company expects its effective interest rate to rise near the high end of a 100 to 200 basis point range, and covenant leverage limits were temporarily loosened.

Results Inside the Range, Debt Rebuilt

Integra LifeSciences (NASDAQ:IART), the Princeton, New Jersey maker of neurosurgery products, surgical instruments and tissue repair products, reported third-quarter results at 6:00 a.m. ET on Wednesday, October 21, 2026. Revenue rose 2.3% to USD 411.2 million, or 2.5% on an organic basis, after a Cincinnati flood cost about USD 7 million of sales. Specialty Surgery grew 4.2% organically to USD 304.1 million, led by Neuro at 6.5%, while Tissue Reconstruction fell 2.2% to USD 107.1 million. Adjusted EPS was USD 0.59, against the consensus estimate of USD 0.56 and USD 0.54 a year earlier. GAAP net income was USD 14.9 million, or USD 0.19 per share, against a loss a year earlier. Adjusted gross margin eased to 61.1% from 62.9%.

How the Refinancing Trades Cost for Headroom

For Integra LifeSciences (NASDAQ:IART), the refinancing completed on Monday, October 19, 2026 totals USD 2.1 billion. It comprises a USD 1.65 billion senior secured credit facility, split into a USD 600 million Term Loan A, a USD 600 million revolving credit line and a USD 450 million Term Loan B, plus USD 450 million of 9.5% senior secured notes due 2033. Senior secured means lenders hold a claim on company assets ahead of other creditors. The company expects its effective interest rate to rise near the high end of a 100 to 200 basis point range. In return, the maximum permitted net leverage was raised temporarily, with a step-down to 4.25 times during 2027, against 4.0 times previously. That headroom matters because leverage stands at 3.8 times.

Risks and What to Watch

The first risk for Integra LifeSciences (NASDAQ:IART) is interest cost: a higher effective rate absorbs cash that could otherwise reduce debt, and full-year operating cash flow is guided at about USD 190 million to USD 200 million. The second is covenant headroom, since leverage of 3.8 times sits close to the 4.25 times limit that applies during 2027. The third is the manufacturing transition: Braintree transition charges were USD 8.8 million in the quarter, and the SurgiMend relaunch is planned for the fourth quarter. Fourth-quarter revenue guidance of USD 413 million to USD 433 million implies a reported change of minus 5.2% to minus 0.5%. Investors should watch the Fed decision on Wednesday, October 28, 2026, the SurgiMend relaunch and fourth-quarter adjusted EPS against USD 0.61 to USD 0.71.

Where Things Stand

The answer is that Integra LifeSciences (NASDAQ:IART) accepted a higher interest cost, including 9.5% on its new notes, in exchange for funding to 2033 and looser covenant limits. The quarter itself landed inside guidance: adjusted EPS of USD 0.59 beat the USD 0.56 consensus, free cash flow more than tripled to USD 85.7 million and net debt fell to USD 1.52 billion. The next catalysts are the Fed decision on October 28, the SurgiMend relaunch and fourth-quarter results. Guidance is a company forecast, not a guarantee, and this is not investment advice.